Caldus


MARKET OPPORTUNITY

 

CLINICAL

  • Ablation of pathologic soft tissues including tumors
  • Renal denervation for refractory hypertension

 

TOTAL/IMMEDIATE ADDRESSABLE MARKET

  • General soft tissue ablation ~$200M/$100M1
  • Renal denervation ~$5B/$1B2

 

CURRENT DEVICE LIMITATIONS

  • Expensive, difficult to maintain capital equipment (console) required to generate ablation energy
  • Complex algorithms and other features necessary to achieve wide ablation field
  

PAVMED SOLUTION

 

CALDUS

  • Completely disposable tissue ablation devices including for renal denervation
  • Direct thermal ablation using proprietary infusion device and continuous flow balloon catheter

 

MORE COST EFFECTIVE

  • No capital and maintenance costs
  • Lower procedural cost while maintaining margin
  • Higher temperatures allow shorter ablation times

 

EXPANDED MARKET

  • Lower distribution costs to OUS markets
  • Attractive to emerging markets with limited resources to distribute and maintain capital equipment



This product is in the development phase and has yet to receive regulatory approval.